Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
The BSGM news archive on Stock Titan covers the corporate evolution of BioSig Technologies, Inc. into Streamex Corp., a Nasdaq-listed company now trading under the symbol STEX. Company press releases and SEC-referenced announcements document the merger between BioSig Technologies and Streamex Exchange Corporation, the subsequent name change to Streamex Corp., and the ticker change from BSGM to STEX on the Nasdaq Capital Market.
Earlier news items in this history describe BioSig’s activities as a medical device technology company focused on the PURE EP™ Platform for electrophysiology procedures. More recent releases highlight the company’s strategic pivot toward real-world asset tokenization and gold-focused financial infrastructure through Streamex. Disclosures discuss Streamex as a gold tokenization and gold treasury business building institutional-grade infrastructure to bring the gold and commodities markets on chain.
Readers can find coverage of key developments such as the closing of the merger with Streamex Exchange Corporation, public offerings of common stock to purchase gold bullion under an investment policy, and a tokenized yield partnership agreement related to precious-metal lease and bond programs. News items also address plans to operate as a regulated participant in tokenized real-world asset markets, including engaging a specialist firm to manage the acquisition of a FINRA and SEC-registered broker-dealer.
For anyone tracking the company’s journey from its BSGM days to its current STEX identity, this news page provides a chronological view of material announcements, strategic partnerships, capital markets activity, and governance changes that define the transition from a medical device issuer to a gold tokenization and RWA-focused enterprise.
BioSig Technologies announced FDA approval to proceed with a Phase II clinical trial for its antiviral drug, merimepodib, aimed at treating COVID-19 in hospitalized patients requiring oxygen support. This study will be randomized and placebo-controlled, involving multiple centers including three Mayo Clinic sites. The trial's success could signify a breakthrough in COVID-19 treatment options. The company emphasizes the drug's broad-spectrum activity against COVID-19, positioning it as a potential pivotal solution amid the pandemic.
BioSig Technologies (BSGM) announced positive pre-clinical results for merimepodib in combination with remdesivir, showing a significant reduction of SARS-CoV-2 viral production to undetectable levels. This study, conducted at the Galveston National Laboratory, underscores the potential of merimepodib as both a standalone treatment and in synergy with remdesivir. The first clinical trial is planned for hospitalized patients requiring supplemental oxygen, evaluating the drug's effectiveness. The results aim to pave the way for a phase 2 study upon FDA clearance.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced the appointment of Mr. Michael Schmertzler to the Board of Directors of its subsidiary, ViralClear Pharmaceuticals, Inc. Schmertzler brings extensive experience in biotechnology, including his role as Chairman of PTC Therapeutics since 2004. He has been pivotal in various biotech ventures and possesses a strong financial background with investment banks. ViralClear focuses on developing merimepodib, an anti-viral candidate targeting RNA viruses, which has shown significant potential against COVID-19 in preliminary studies.
BioSig Technologies, Inc. (NASDAQ: BSGM) has appointed Mr. Dennis Purcell to the Board of Directors of its subsidiary ViralClear Pharmaceuticals. Purcell is a seasoned life sciences investor, founder of Aisling Capital, and former Managing Director at Chase H&Q, involved in over $10 billion of financing transactions. ViralClear is developing merimepodib, an antiviral candidate showing promise against COVID-19. Mayo Clinic will be a site for a Phase II trial, with results expected within three months. The company aims to leverage Purcell's expertise as it advances its clinical programs.
Summary not available.
Summary not available.